Background: As the population ages, the number of people living with Alzheimer’s disease (AD) has been increasing over time. Between 1999 and 2006, four new AD drugs were approved for insurance coverage in Taiwan. Aims of the Study: We investigate the heterogeneous influences of adopting these new drugs on healthcare expenditures. We also evaluate whether […]